The fourth Xarelto-related
product liability case to go to trial went to the jury on Friday as attorneys
accused Johnson and Johnson and Bayer of deliberately understating the risks of
serious internal bleeding associated with the blockbuster drug. This
case was tried in Pennsylvania state court, and not through the Federal MDL out
of New Orleans.
The case is one of more than 1,500 Xarelto-related cases pending as part of a mass tort program in the Philadelphia County Court of Common Pleas. The prior three trials in the MDL resulted in verdicts for the Defendants.
The case centered on arguments that the drugmakers failed to include information in Xarelto’s warning label indicating that the rate of bleeding events observed in a clinical trial was significantly higher among patients in the United States than patients elsewhere in the world. According to evidence in the case, the rate among participants in the United States was 8.1 percent annually versus 3.6 percent annually among participants globally. The label was ultimately updated in September 2015 to include such information.
Pittman, Dutton & Hellums, P.C., is currently investigating Xarelto cases. If you or a loved one were prescribed Xarelto and suffered an irreversible internal bleeding that lead to hospitalization and/or death, contact Booth Samuels at toll free 1-866-515-8880 or by email at booths@pittmanudutton.com.
The case is one of more than 1,500 Xarelto-related cases pending as part of a mass tort program in the Philadelphia County Court of Common Pleas. The prior three trials in the MDL resulted in verdicts for the Defendants.
The case centered on arguments that the drugmakers failed to include information in Xarelto’s warning label indicating that the rate of bleeding events observed in a clinical trial was significantly higher among patients in the United States than patients elsewhere in the world. According to evidence in the case, the rate among participants in the United States was 8.1 percent annually versus 3.6 percent annually among participants globally. The label was ultimately updated in September 2015 to include such information.
Pittman, Dutton & Hellums, P.C., is currently investigating Xarelto cases. If you or a loved one were prescribed Xarelto and suffered an irreversible internal bleeding that lead to hospitalization and/or death, contact Booth Samuels at toll free 1-866-515-8880 or by email at booths@pittmanudutton.com.
